Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022
May 09, 2022 at 04:10 pm EDT
Share
Heron Therapeutics, Inc. provided revenue guidance for the second quarter and full year 2022. Heron currently expects the second quarter of 2022 net product sales for the oncology care franchise in the range of $22 million to $23 million.
The company expects full-year 2022 net product sales for the oncology care franchise in the range of $89 million to $93 million.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.
HERON THERAPEUTICS, INC. 
